Kiromic BioPharma is a cell therapy company that uses artificial intelligence to develop allogeneic T cell therapies to target solid tumors. The company has developed two product candidates, ALEXIS-ISO-1 and ALEXIS-PRO-1, which target Isomesothelin and PD-L1, respectively. Kiromic BioPharma has several license and collaboration agreements and is based in Houston, Texas.